This so-called “chronic active” signaling was required for cell survival, therefore, highlighting a role for the BCR clusters and the signaling they induce in activated B-cell-like DLBCL, and revealing a possible new treatment target. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.